Researchers Find a Drug That Can Inhibit COVID-19 Virus Replication By Up to 5000 Fold

Every few years, a new virus outbreak occurs that affects thousands of people such as the SARS-CoV in 2003, Ebola in 2014, and now the SARS-CoV-2 since December 2019. These frequent outbreaks have proved to be especially challenging as treatment discoveries have a time constraint.



Read Also: 31 Existing Antiviral Drugs Are Now Being Considered for the Wuhan Coronavirus

SARS-CoV-2 results in COVID-19, which has flu-like symptoms ranging from mild disease to severe lung injury and multi-organ failure, eventually leading to death, especially in older patients with other co-morbidities. Since the WHO declaration of COVID-19 to be a public health emergency of pandemic proportions, researchers around the world have been racing against time to find an effective treatment.

The University of British Columbia published results of a clinical trial recently that have promising findings of a potentially effective drug. According to the researchers, hrsACE2, which has already been tested in phase 1 and phase 2 clinical trials, can reduce viral growth by a factor of 1,000-5,000.

The study found the receptor-binding domain (RBD) of SARS-CoV-2 to be remarkably similar to the SARS-CoV RBD, signifying a similar host cell receptor. Additionally, the researchers found ACE2 to be the functional SARS-CoV receptor by in vitro study.

A study conducted on mice found overexpression of ACE2 to enhance the severity of disease in mice infected with SARS-CoV. This indicates that ACE2-dependent viral entry into cells is a critical factor for morbidity. Injecting SARS-CoV spike into mice decreased ACE2 expression levels, thereby worsening lung injury.

Recent studies have shown that SARS-CoV-2 spike protein directly binds to ACE2 and that the SARS-CoV-2 spike protein recognizes human ACE2 with an even higher binding affinity than Spike from SARS-CoV.

In the human lungs, ACE2 is found mainly in alveolar epithelial type II cells, which can also act as viral storage. These cells synthesize surfactant which lessens surface tension inhibiting alveolar collapse. Therefore, they are essential to the lung’s gas exchange function. In COVID-19, the severity of the illness can be attributed to the damage of the alveolar epithelial type II cells, that express ACE2.

Related: Coronavirus Pandemic: Why Knowing Your HIV Status Could save Your Life

Apart from the lungs, ACE2 is also expressed in the heart, kidneys, blood vessels, and intestine. This explains the multiorgan dysfunction seen in COVID-19 patients.

According to the researchers, clinical-grade human recombinant soluble ACE2 can reduce viral growth in COVID-19 infected cells by a factor of 1,000-5,000. The drug has already been tested in phase 1 and phase 2 clinical trials. Furthermore, hrsACE2 can inhibit the infection of human blood vessels and kidneys even at the early stages of infection.

The researchers aimed to provide direct evidence that clinical-grade hrsACE2 can indeed interfere with SARS-CoV-2 infections. At first, they infected cells with varying numbers of SARS-CoV-2. Next using qRT-PCR, Viral RNA was purified from cells and assayed to use as a marker for replication.

Infection of cells in the presence of hrsACE2 during 1 hr, followed by washing and incubation without hrsACE2 significantly inhibited SARS-CoV-2 infections 15 hours post-infection.

Boost Immune System With Immune Defence


The team led by University of British Columbia researcher Dr. Josef Penninger has found hrsACE2 to effectively block the receptor SARS-CoV-2 uses to infect its hosts.

“Our new study provides very much needed direct evidence that a drug — called APN01 (human recombinant soluble angiotensin-converting enzyme 2 — hrsACE2) — soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19,” says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael’s Hospital and professor at the University of Toronto who is a collaborator on the study.

Emergency funding to combat the COVID-19 outbreak from the Canadian federal government has supported part of the research.


Related Articles:

Coronavirus Treatments: Schweppes Tonic and Canada Dry Do Not Contain Chloroquine

Are Masks Effective in the Fight Against the Coronavirus Epidemic?

Coronavirus Pandemic: Is Global Shutdown Crucial or an Exaggerated Response?

Coronavirus Latest Facts: What Is It And What Are Its Symptoms?

Guideline to Self-Quarantine During the Coronavirus Outbreak

Gilmore Health

Study Shows That the Coronavirus Can Also Be Spread Through Fecal Matter

Why Does Italy Have the Highest Death Rate From Coronavirus?

Coronavirus: Are We Heading Towards a Pandemic?

When Do Symptoms Start to Show Following Coronavirus Infection?





Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.